Spots Global Cancer Trial Database for Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Official Title: An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Study ID: NCT04198766
Study Description
Brief Summary: This is a Phase 1/2, open-label, non-randomized, 4-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope, Duarte, California, United States
Valkyrie Clinical Trials, Los Angeles, California, United States
St. Joseph Hospital of Orange, Orange, California, United States
Winship Cancer Institute - Emory University, Atlanta, Georgia, United States
The University of Chicago Medical Center, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Henry Ford Cancer Institute, Detroit, Michigan, United States
START Midwest, Grand Rapids, Michigan, United States
Nebraska Cancer Specialists, Omaha, Nebraska, United States
Providence Portland Medical Center, Portland, Oregon, United States
Vanderbilt University School of Medicine, Nashville, Tennessee, United States
Renovatio Clinical - El Paso, El Paso, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
Renovatio Clinical, The Woodlands, Texas, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact Details
Name: Josep Garcia, PhD
Affiliation: Inhibrx, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
